Subhangi Das, Bankura Sammilani College
SARS-COV2 infection causing COVID-19 disease can lead to severe multi – organ injuries and significant mortality in critical patients, particularly among those people with type 2 diabetes (T2D) as a comorbidity. These patients have worse outcomes as compared to the ones without diabetes mellitus. Although attenuated mortality was observed with aggressive glucose control, the benefit of therapeutic regiments including insulin treatment for patients with COVID-19 and T2D remains unclear.
On conducting a study in Wuhan, China which investigated 689 patients with COVID-19 and T2D from a cohort of 3,305 cases, it was found that insulin treatment for patients with COVID-19 and T2D was related with a huge expansion in mortality [27.2% versus 3.5%; changed HR, 5.38 (2.75-10.54)]. It was found that enhanced inflammation and injury of vital organs was associated with insulin treatment during the progression of COVID19 symptoms in patients with T2D.
Thus, insulin treatment for patients with COVID-19 and T2D should be utilized with alert. Further the patients with COVID-19 and T2D should be closely monitored for blood – glucose, vital signs, and organ injuries when treated with insulin.
Also read: An eye exam with AI to achieve early Parkinson’s detection?
Reference: Insulin treatment is associated with increased mortality in patients with COVID-19 Bo Yu, MD, PhD, Chenze Li, MD, PhD, Yang Sun, MD, PhD, Dao Wen Wang, MD, PhD. Cell Metabolism. , doi: https://doi.org/10.1016/ j.cmet.2020.11.014.
2 thoughts on “Insulin treatment associated with mortality in patients with COVID-19 and Type 2 diabetes”